Keywords: لنفنگیلیمیومیتوزیس; Lymphangioleiomyomatosis; Chylothorax; Chylous ascites; Chyluria; Sirolimus; Ezetimibe;
مقالات ISI لنفنگیلیمیومیتوزیس (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: لنفنگیلیمیومیتوزیس; ADHD; attention-deficit/hyperactivity disorder; ASD; autism spectrum disorder; ICF; International Classification of Functioning, Disability, and Health; ID; intellectual disability; LAM; lymphangioleiomyomatosis; MEC; Medical and Ethical Review Committee;
Keywords: لنفنگیلیمیومیتوزیس; Lymphangioleiomyomatosis; EGFR; HER2; HER3; HER4;
Keywords: لنفنگیلیمیومیتوزیس; Abdominal neoplasm; Lymphangioleiomyomatosis; Surgery; Radiotherapy; Sirolimus;
Keywords: لنفنگیلیمیومیتوزیس; Lymphangioleiomyomatosis; PEComa; Retroperitoneum; Extrapulmonary clear cell tumor; Lymphangioleiomyoma;
Keywords: لنفنگیلیمیومیتوزیس; Lymphangioleiomyomatosis; Sirolimus; Chylothorax;
Keywords: لنفنگیلیمیومیتوزیس; interstitial lung disease; parenchymal lung disease; pulmonary hypertension; 6MWT; 6-min walk testing; Dlco; diffusion capacity for carbon dioxide; ECHO; echocardiogram; HRR; heart rate recovery; ILD; interstitial lung disease; IPF; idiopathic pulmonary f
Keywords: لنفنگیلیمیومیتوزیس; autophagy; FEV1; lymphangioleiomyomatosis; sirolimus; VEGF-D; 6-MWD; 6-min walk distance; AML; angiomyolipoma; Dlco; diffusion coefficient for carbon monoxide; DLT; dose-limiting toxicity; LAM; lymphangioleiomyomatosis; MTD; maximal tolerated dose; NCI; N
Keywords: لنفنگیلیمیومیتوزیس; lymphangioleiomyomatosis; pelvic pain; retroperitoneum
Keywords: لنفنگیلیمیومیتوزیس; Database; Disease progression; Pulmonary function; Lymphangioleiomyomatosis; Rare lung disease
Keywords: لنفنگیلیمیومیتوزیس; Airway obstruction; VEGF-D; HIF-1α; Lung transplantation; Lymphangiogenesis; Lymphangioleiomyomatosis; mTORC1;
Keywords: لنفنگیلیمیومیتوزیس; Tuberous sclerosis; MR imaging; Tuber; Subependymal giant cell astrocytoma (SEGA); mTOR; Angiomyolipoma; Lymphangioleiomyomatosis;
Keywords: لنفنگیلیمیومیتوزیس; blood supply; bronchoscopy; vascular; vessels; AVM; arteriovenous malformation; DL; Dieulafoy lesion; ET; endobronchial telangiectasia; FM; fibrosing mediastinitis; HHT; hereditary hemorrhagic telangiectasia; KL; kaposiform lymphangiomatosis; LAM; lymphan
Keywords: لنفنگیلیمیومیتوزیس; cystic lung disease; diffuse lung disease; focal lung luciencies; lung cysts; pulmonary cysts; BHD; Birt Hogg Dubé; DIP; desquamative interstitial pneumonia; HRCT; high-resolution CT scan; LAM; lymphangioleiomyomatosis; LCDD; light-chain deposition disea
Keywords: لنفنگیلیمیومیتوزیس; genital track; lymphangioleiomyomatosis; metastasis; tuberous sclerosis; uterus
Keywords: لنفنگیلیمیومیتوزیس; Lymphangioleiomyomatosis; Uterine tumor; Retroperitoneal tumor; Sirolimus; KL-6
Keywords: لنفنگیلیمیومیتوزیس; Lymphangioleiomyomatosis; Lung transplantation; Sirolimus; Outcome; 6MWT; 6-min walking test; DLT; double lung transplant; ECHO; echocardiogram; FEV1; forced expiratory volume in one second; LAM; lymphangioleiomyomatosis; LT; lung transplantation; MILES;
Keywords: لنفنگیلیمیومیتوزیس; Thoracic imaging; Quantitative methods; Computed tomography; Lymphangioleiomyomatosis
Keywords: لنفنگیلیمیومیتوزیس; IQR; interquartile range; LAM; lymphangioleiomyomatosis; LCC; lymphangioleiomyomatosis cell cluster; NHLBI; National Heart, Lung, and Blood Institute; VEGF; vascular endothelial growth factor;
Keywords: لنفنگیلیمیومیتوزیس; Lymphangioleiomyomatosis; Tuberous sclerosis; Computed tomography;
Keywords: لنفنگیلیمیومیتوزیس; Dlco; diffusing capacity of the lung for carbon monoxide; GTP; guanosine triphosphate; GTPase; guanosine triphosphatase; LAM; lymphangioleiomyomatosis; mTOR; mechanistic target of rapamycin; Rheb; Ras homolog enriched in brain; TSC; tuberous sclerosis com
Keywords: لنفنگیلیمیومیتوزیس; ICD; International Classification of Diseases; LAM; lymphangioleiomyomatosis; RAMQ; Régie de l'Assurance-Maladie du Québec; TSC; tuberous sclerosis complex;
Keywords: لنفنگیلیمیومیتوزیس; Lymphangioleiomyomatosis; Extrapulmonary; Uterine cancer; Pelvic lymph node; Immunohistochemistry; Infangioleiomiomatosis; Extrapulmonar; Cáncer uterino; Ganglios linfáticos pélvicos; InmunohistoquÃmica;
Keywords: لنفنگیلیمیومیتوزیس; Mediastinal; Linfangioleiomioma; LinfangioleiomiomatoseMediastinal; Lymphangioleiomyoma; Lymphangioleiomyomatosis
Keywords: لنفنگیلیمیومیتوزیس; BHD; Birt-Hogg-Dubé syndrome; CPAM; congenital pulmonary airway malformation; HRCT; high-resolution CT; LAM; lymphangioleiomyomatosis; TTNB; transthoracic needle biopsy;
Keywords: لنفنگیلیمیومیتوزیس; DCLD; diffuse cystic lung disease; HRCT; high-resolution CT; LAM; lymphangioleiomyomatosis; PLCH; pulmonary Langerhans cell histiocytosis;
Métastases pulmonaires bénignes d'un léiomyome
Keywords: لنفنگیلیمیومیتوزیس; Métastases bénignes de léiomyomes; Nodules pulmonaires; Lymphangioléiomyomatose; Benign metastasizing leiomyoma (BML); Pulmonary nodules; Lymphangioleiomyomatosis;
Superselective Transcatheter Arterial Embolization for Large Unruptured Renal Angiomyolipoma in Lymphangioleiomyomatosis
Keywords: لنفنگیلیمیومیتوزیس; AML; angiomyolipoma; GSP; gelatin sponge particle; LAM; lymphangioleiomyomatosis; TAE; transcatheter arterial embolization; TSC; tuberous sclerosis complex;
In situ analysis of mTORC1/2 and cellular metabolism-related proteins in human Lymphangioleiomyomatosis
Keywords: لنفنگیلیمیومیتوزیس; ACSS2; acyl-coenzyme A synthetase short-chain family member 2; ATPB; β-F1-ATPase; BSM; bronchial smooth muscle; CPT1A; carnitine palmitoyltransferase 1A; ER; estrogen receptor; GAPDH; glyceraldehyde 3-phosphate dehydrogenase; GLS; glutaminase; GLUT1; glu
Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis
Keywords: لنفنگیلیمیومیتوزیس; lung function; lymphangioleiomyomatosis; lymphatic disease; sirolimus; VEGF-D; AML; angiomyolipoma; Dlco; diffusion capacity for carbon monoxide; LAM; lymphangioleiomyomatosis; MILES; Multicenter International Lymphangioleiomyomatosis Efficacy and Safety
Original contributionAngiomyomatous hamartoma of lymph nodes, revisited: clinicopathologic study of 21 cases, emphasizing its distinction from lymphangioleiomyomatosis of lymph nodesâ
Keywords: لنفنگیلیمیومیتوزیس; Angiomyomatous hamartoma; Lymph node; Cathepsin K; HMB-45; Lymphangioleiomyomatosis;
Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells
Keywords: لنفنگیلیمیومیتوزیس; LAM; lymphangioleiomyomatosis; LOH; loss of heterozygosity; TPN; total parenteral nutrition; TSC; tuberous sclerosis complex; VEGF-D; vascular endothelial growth factor D;
Therapeutic Application of Percutaneous Peritoneovenous (Denver) Shunt in Treating Chylous Ascites in Cancer Patients
Keywords: لنفنگیلیمیومیتوزیس; CA; chylous ascites; DIC; disseminated intravascular coagulopathy; LAM; lymphangioleiomyomatosis; LND; lymph node dissection; PPVS; percutaneous peritoneovenous shunt;
Inhibition of versican expression by siRNA facilitates tropoelastin synthesis and elastic fiber formation by human SK-LMS-1 leiomyosarcoma smooth muscle cells in vitro and in vivo
Keywords: لنفنگیلیمیومیتوزیس; ECM; extracellular matrix; α-GAG; α-glycosaminoglycan; β-GAG; β-glycosaminoglycan; CS; chondroitin sulfate; SMCs; smooth muscle cells; LAM; lymphangioleiomyomatosis; COPD; chronic obstructive pulmonary disease; LMS; leiomyosarcoma; IHC; immunohistoche
Rapamycin requires AMPK activity and p27 expression for promoting autophagy-dependent Tsc2-null cell survival
Keywords: لنفنگیلیمیومیتوزیس; AMPK; 5â² AMP-activated protein kinase; Atg13; autophagy-related protein 13; CDK; cyclin-dependent kinase; DAPI; 4â²,6-diamidino-2-phenylindole; DMEM; Dulbecco's modified eagle's medium; DMSO; dimethyl sulfoxide; FDA; US Food and Drug Administration; GF
Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus
Keywords: لنفنگیلیمیومیتوزیس; angiofibromas; lymphangioleiomyomatosis; mechanistic target of rapamycin inhibitor; shagreen patch; sirolimus; tuberous sclerosis complex; ungual fibromaLAM, lymphangioleiomyomatosis; mTOR, mechanistic target of rapamycin; PGA, Physician Global Assessment
Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis
Keywords: لنفنگیلیمیومیتوزیس; Lymphangioleiomyomatosis; Lymphangioma; Pulmonary function tests; Renal angiomyolipomas; Tuberous sclerosis; VEGF-D;
PEComa: morphology and genetics of a complex tumor family
Keywords: لنفنگیلیمیومیتوزیس; Perivascular epithelioid cell tumor; Angiomyolipoma; Clear cell myomelanocytic tumor; Lymphangioleiomyomatosis; TFE3; Tuberous sclerosis; Sirolimus
Protocolo diagnóstico, pronóstico y terapéutico de las enfermedades intersticiales quÃsticas
Keywords: لنفنگیلیمیومیتوزیس; Llinfangioleiomiomatosis; Histiocitosis de células de Langerhans; Enfermedades pulmonares quÃsticas; Lymphangioleiomyomatosis; Langerhans cell histiocytosis; Cystic lung diseases;
Phenotypes associated with inherited and developmental somatic mutations in genes encoding mTOR pathway components
Keywords: لنفنگیلیمیومیتوزیس; mTOR; Mamalian target of rapamycin; PI3K; phosphoinositide 3-kinase related kinase; mTORC1; mTOR complex 1; mTORC2; mTOR complex 2; AMP; Adenosine monophosphate; ATP; Adenosine triphosphate; S6K; ribosomal S6 Kinase; 4E-BP1; eukaryotic initiation factor 4
Genetics of rare mesenchymal tumors: Implications for targeted treatment in DFSP, ASPS, CCS, GCTB and PEComa
Keywords: لنفنگیلیمیومیتوزیس; DFSP; dermatofibrosarcoma protuberans; ASPS; alveolar soft part sarcoma; CCS; clear cell sarcoma; GCTB; giant cell tumor of bone; PEComas; perivascular epithelioid cell neoplasm; PDGFRB; platelet-derived growth factor receptor, beta; MET; met proto-oncoge
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Keywords: لنفنگیلیمیومیتوزیس; PI3K pathway; Targeted therapy; Predictive biomarkers; 4EBP1; 4E-binding protein 1; AKT; protein kinase-B; AMPK; AMP-activated protein kinase; COSMIC; Catalogue of Somatic Mutations in Cancer; eIF4E; eukaryotic initiation factor 4E; ERK; extracellular-sig
Le syndrome de Protée : une cause exceptionnelle d'emphysème pulmonaire
Keywords: لنفنگیلیمیومیتوزیس; Syndrome de Protée; Emphysème; Kystes pulmonaires; AKT1; Lymphangioléiomyomatose; Proteus syndrome; Emphysema; Pulmonary cysts; AKT1; Lymphangioleiomyomatosis;
A pilot study assessing the effect of bronchodilator on dynamic hyperinflation in LAM
Keywords: لنفنگیلیمیومیتوزیس; Adrenergic beta-2 receptor agonists; Exercise test; Lymphangioleiomyomatosis; Pulmonary function tests;
The efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis
Keywords: لنفنگیلیمیومیتوزیس; Chylous effusion; Lymphangioleiomyomatosis; mTOR inhibitor; Sirolimus;
Trasplante pulmonar en la linfangioleiomiomatosis esporádica. Estudio de 7 casos
Keywords: لنفنگیلیمیومیتوزیس; Linfangioleiomiomatosis; Trasplante pulmonar; Enfermedades raras; Lymphangioleiomyomatosis; Lung transplant; Rare diseases;
Facteurs étiologiques
Keywords: لنفنگیلیمیومیتوزیس; Pneumothorax secondaire; Bulle; Syndrome de Birt-Hogg-Dubé; Lymphangioléiomyomatose; Histiocytose langerhansienne; Secondary pneumothorax; Bullae; Birt-Hogg-Dubé syndrome; Lymphangioleiomyomatosis; Langerhans cell histiocytosis;
World Health Organization Group 5 Pulmonary Hypertension
Keywords: لنفنگیلیمیومیتوزیس; Sarcoidosis; Lymphangioleiomyomatosis; Pulmonary Langerhans cell histiocytosis; Renal failure; Splenectomy; Fibrosing mediastinitis; Myeloproliferative disorders; Metabolic disorders;
Linfangioleiomiomatosis esporádica e hipertensión pulmonar. Estudio clÃnico-patológico en pacientes receptoras de un trasplante pulmonar
Keywords: لنفنگیلیمیومیتوزیس; Linfangioleiomiomatosis; Hipertensión pulmonar; Trasplante pulmonar; Enfermedades raras; Lymphangioleiomyomatosis; Pulmonary hypertension; Lung transplantation; Rare diseases;
Systemic diseases and the lung
Keywords: لنفنگیلیمیومیتوزیس; Churg–Strauss; lupus; lymphangioleiomyomatosis; lymphoma; orphan lung; rheumatoid; sclerosis; Wegener's